Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Amneal Pharmaceuticals IncAMRX67.541.01-157.7211.23-148.99%1.29%29.30$8.38$113.4440,894$8.47

Detail of Amneal Pharmaceuticals Inc

 
CEO
Mr. Chirag K. Patel
Employees
7850
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Market cap
$3B

Company details

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OTH
OI
OIE
PI
TAX
NI
Revenue (Rev)
$2.60B
Cost of goods (CoG)
-$1.69B
Gross profit (GP)
$910.36M
Operating expense (OE)
-$617.34M
Research and development (R&D)
-$166.20M
General and administrative (G&A)
-$451.07M
Other (OTH)
-$73,000.00
Operating income (OI)
$277.63M
Other income expense (OIE)
-$110.57M
Pretax income (PI)
-$115.62M
Tax (TAX)
-$17.58M
Net income (NI)
-$133.20M
Amneal Pharmaceuticals Inc
AMRX • XNYS • US
$8.47
+4.31 (103.61%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
$0.13
Margin profit
-6.72%
52 week low
$4.06
52 week high
$8.935
50-day simple moving average
$8.52
200-day simple moving average
$8.38
Percent held by insiders
54.31%
Percent held by institutions
44.02%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
AMRX +97.90%
eps change
AMRX -75.00%